You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The seven-year grant renews funding for the Antibacterial Resistance Leadership Group, led by Duke University and UCSF, with $15 million in 2020.
News items for the week of Dec. 9, 2019.
Tempus said that Akesogen's lab provides a range of testing services, including for inherited risk of cancer, microbiome profiling, whole-genome genotyping, and more.
The companies will identify and optimize novel CRISPR proteins owned by Mammoth, and then license those proteins to Horizon for use in engineered cell lines.
AbbVie researchers validated and extended a previous study to find different types of genetic evidence have varying influences on approval prospects.
Absent sufficient evidence to support genetic testing for all patients, the group recommended following existing guidelines, which are based on clinical factors.
Australian researchers have developed a predictive lifespan clock based on CpG density at 42 different promoter sites.
A genome-wide association study meta-analysis of eight psychiatric conditions led to new and known risk loci, and revealed three distinct groups of conditions.
Prescient offers a test that is designed to determine an individual's risk of opioid addiction by analyzing 16 genes in the brain's reward pathway.
Researchers identified 10 protein-based tumor subtypes across five cancer types, including subtypes representing immune cell features in the tumor microenvironment.
A study found that participants who used the Genomics ADvISER decision aid before a genetic counseling session needed less time than those who did not.
The firm completed financing actions raising around $1.2 billion in funds that it plans to use to provide financial flexibility and fund corporate objectives.
Included in the deal is Diagnomics' minority stake in the Eone-Diagnomics Genome Center, a Korean provider of clinical and consumer genetics products and services.
Pressure associated with competition and reimbursement may erode GenMark's market share and product pricing, JP Morgan said.
The firm reported full year revenues of $54.4 million and fiscal Q4 revenues of $15.7 million, beating the consensus Wall Street estimates for both.
The sites include Massachusetts General Hospital, Northwestern Medicine, Struthers Parkinson's Center, UC San Diego, and the Perelman School of Medicine.
The UK-based company's revenues are generated exclusively from epigenetic biomarker research and development alliances with commercial and academic partners.
In a proof-of-principle study, Ohio State University researchers compared the nanopore sequencing assay to short-read sequencing and capillary electrophoresis.
The genomics-focused fertility management company claims that 23andMe failed to meet its contractual obligations within a research collaboration.
The firm also said it is contemplating selling its therapeutics division, and appointed David Bench as its new CFO.
The Genome Program, led by technology firm Group 42 in collaboration with BGI and Oxford Nanopore, plans to sequence 100,000 samples during its first phase.
The firm took down all of its global information technology systems following a ransomware attack last Thursday.
The chip will include coding SNPs identified by Medicinal Genomics using its Kannapedia cannabis genomic database, according to Eurofins.
The Atlantic reports another SARS-CoV-2 testing problem may be lurking: backlogs.
Researchers have sequenced the genome of "the Methuselah of freshwater fish."
The US Biomedical Advanced Research and Development Authority is supporting efforts to develop vaccines against SARS-CoV-2.
In Genome Biology this week: difference in methylation in neurons from Parkinson's disease patients, differential expression analysis by barcoded sequencing approach, and more.